Joint Formulary & PAD

Sarilumab - Juvenile idiopathic arthritis (children)

You are here : Home > Formulary Search > Sarilumab - Juvenile idiopathic arthritis (children)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Pre-filled pen
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NFD2
SPC
Restrictions / Comments :

This drug has not yet been assessed for formulary status.
NICE is unable to make a recommendation because the company has not provided an evidence submission. NICE therefore terminated its appraisal and as such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
If a specialist team would like the APC to consider adding this treatment to the Joint Formulary. They should contact the team at syheartlandsicb.apc@nhs.net and the team will provide support for the submission.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Sarilumab
Indication :
Juvenile idiopathic arthritis (children)
Group Name :
Keywords :
Polyarticular, oligoarticular, JIA, Children and Young People
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (0)

  • No records returned.

Other Indications

Below are listed other indications that Sarilumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Juvenile idiopathic arthritis (children).

  • No records returned.